Skip to main content

Table 1 Clinicopathological characterization of patients included in the training datasets

From: Identification of an immune classification for cervical cancer and integrative analysis of multiomics data

Variable Group P value
Active immune (n = 153) Exhausted (n = 74) Non-immune (n = 64)
Age 48.86 (14.29) 47.31 (14.00) 47.17 (12.43) 0.611
BMI 28.54 (8.52) 27.60 (6.32) 26.92 (5.97) 0.366
Smoke 0.852
 Yes 32 (20.9%) 19 (25.7%) 12 (18.8%)  
 No 101 (66.0%) 46 (62.2%) 45 (70.3%)  
 Unknown 20 (13.1%) 9 (12.2%) 7 (10.9%)  
HPV state 0.002
 Positive 147 (96.1%) 70 (94.6%) 53 (82.8%)  
 Negative 6 (3.9%) 4 (5.4%) 11 (17.2%)  
HPV16/18 state  < 0.001
 Positive 107 (69.9%) 42 (56.8%) 39 (60.9%)  
 Negative 45 (29.4%) 32 (43.2%) 13 (20.3%)  
 Unknown 1 (0.7%) 0 (0.0%) 12 (18.8%)  
Clinical stage 0.121
 Stage I 84 (54.9%) 32 (43.2%) 43 (67.2%)  
 Stage II 35 (22.9%) 18 (24.3%) 11 (17.2%)  
 Stage III 23 (15.0%) 13 (17.6%) 5 (7.8%)  
 Stage IV 7 (4.6%) 9 (12.2%) 5 (7.8%)  
 Unknown 4 (2.6%) 2 (2.7%) 0 (0%)  
Lymph node state 0.289
 Yes 95 (62.1%) 37 (50.0%) 42 (65.6%)  
 No 22 (14.4%) 11 (14.9%) 8 (12.5%)  
 Unknown 36 (23.5%) 26 (35.1%) 14 (21.9%)  
Radiation therapy 0.931
 Yes 77 (50.3%) 35 (47.3%) 31 (48.4%)  
 No 31 (20.3%) 13 (17.6%) 12 (18.8%)  
 Unknown 45 (29.4%) 26 (35.1%) 21 (32.8%)  
Pathological type  < 0.001
 Squamous 150 (98.0%) 73 (98.6%) 18 (28.1%)  
 Adenosquamous 0 (0.0%) 1 (1.4%) 3 (4.7%)  
 Adenocarcinoma 3 (2.0%) 0 (0.0%) 43 (67.2%)